These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 16172253)
1. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Hankins JS; Ware RE; Rogers ZR; Wynn LW; Lane PA; Scott JP; Wang WC Blood; 2005 Oct; 106(7):2269-75. PubMed ID: 16172253 [TBL] [Abstract][Full Text] [Related]
2. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Hankins JS; Aygun B; Nottage K; Thornburg C; Smeltzer MP; Ware RE; Wang WC Medicine (Baltimore); 2014 Dec; 93(28):e215. PubMed ID: 25526439 [TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148 [TBL] [Abstract][Full Text] [Related]
4. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503 [TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea therapy in children severely affected with sickle cell disease. Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542 [TBL] [Abstract][Full Text] [Related]
6. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791 [TBL] [Abstract][Full Text] [Related]
7. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679 [TBL] [Abstract][Full Text] [Related]
8. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Brown AK; Sleeper LA; Miller ST; Pegelow CH; Gill FM; Waclawiw MA Arch Pediatr Adolesc Med; 1994 Aug; 148(8):796-804. PubMed ID: 7519102 [TBL] [Abstract][Full Text] [Related]
9. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Hankins JS; Helton KJ; McCarville MB; Li CS; Wang WC; Ware RE Pediatr Blood Cancer; 2008 Feb; 50(2):293-7. PubMed ID: 17554794 [TBL] [Abstract][Full Text] [Related]
10. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184 [TBL] [Abstract][Full Text] [Related]
11. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146 [TBL] [Abstract][Full Text] [Related]
12. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922 [TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE; N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550 [TBL] [Abstract][Full Text] [Related]
14. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965 [TBL] [Abstract][Full Text] [Related]
15. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience. Youssry I; Abdel-Salam A; Ismail R; Bou-Fakhredin R; Mohamed Samy R; Ezz El-Deen F; Taher AT Hemoglobin; 2017; 41(4-6):267-273. PubMed ID: 29251012 [TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Rogers ZR Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200 [TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813 [TBL] [Abstract][Full Text] [Related]
18. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia. Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115 [TBL] [Abstract][Full Text] [Related]
19. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. Nottage KA; Ware RE; Winter B; Smeltzer M; Wang WC; Hankins JS; Dertinger SD; Shulkin B; Aygun B Eur J Haematol; 2014 Nov; 93(5):377-83. PubMed ID: 24796940 [TBL] [Abstract][Full Text] [Related]
20. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea. Kattamis A; Lagona E; Orfanou I; Psichou F; Ladis V; Kanavakis E; Metaxotou-Mavrommati A; Kattamis C Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]